BioSpace News Archive

Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic diseases, today announced positive topline results from a Phase 3 clinical trial of ecnoglutide (XW003) in Chinese adults with type 2 diabetes mellitus (T2DM).

The venture builder specialized in health has also bolstered its Board of Directors, bringing in Xavier Carbonell and Eva Berenguer, in addition to Albert Mascarell.

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT) today announced new preclinical data on the Company’s lead product candidate, istaroxime, and another preclinical pipeline drug candidate, CVie-216, showing reductions in ventricular arrythmias in a rat heart model of diabetes with restricted and restored coronary blood flow induced injury.

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11, 2024, at 9:45 a.m. PT (12:45 p.m. ET).

Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 7:30 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA.

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA) today announced that Thomas Butler, Biomea Fusion’s Chief Executive Officer and Chairman of the Board, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 from 8:15 am – 8:55 am PST.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Tuesday January 9, 2024 in San Francisco. Kevin Gorman, Chief Executive Officer, will present at the conference.

Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 5:15 p.m. PT/ 8:15 p.m. ET.

Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has completed the acquisition of Motion Solutions.

SAB Biotherapeutics, Inc. announced that it will effect a reverse stock split of its outstanding shares of common stock, effective as of 12:01 a.m. Eastern Time on January 5, 2024.